About SYNCELL
SYNCELL is a company based in Taipei (Taiwan) founded in 2020 by Jung Chi Liao. SYNCELL has raised $15 million across 1 funding round from investors including Taiwania Capital. SYNCELL offers products and services including Microscoop and Reagent Kits. SYNCELL operates in a competitive market with competitors including Nearfield Instruments, Delmic B.V, FlowVIEW Tek, Tiny Bright Things and Envue, among others.
- Headquarter Taipei, Taiwan
- Founders Jung Chi Liao
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Syncell Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15 M (USD)
in 1 rounds
-
Latest Funding Round
$15 M (USD), Series A
Dec 11, 2024
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SYNCELL
SYNCELL offers a comprehensive portfolio of products and services, including Microscoop and Reagent Kits.
Enables high-precision proteomic discovery at cellular and subcellular levels.
Optimized kits for spatial protein purification and integration with platforms.
People of SYNCELL
Unlock access to complete
Funding Insights of SYNCELL
SYNCELL has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series A round of $15 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $15.0M
-
First Round
First Round
(11 Dec 2024)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series A - SYNCELL | Valuation | Taiwania Capital |
|
Investors in SYNCELL
SYNCELL has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Taiwania Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm focusing on technology companies
|
Founded Year | Domain | Location |
Investments & Acquisitions by SYNCELL
Financial Statements - SYNCELL
Syncell Comparisons
Competitors of SYNCELL
SYNCELL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nearfield Instruments, Delmic B.V., FlowVIEW Tek, Tiny Bright Things and Envue, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
High-throughput atomic force microscopy systems for 3D metrology are developed.
|
|
| domain | founded_year | HQ Location |
Provider of light and electron microscopy solutions for life sciences and materials science
|
|
| domain | founded_year | HQ Location |
Liquid monitoring, analysis, and particle detection systems are provided.
|
|
| domain | founded_year | HQ Location |
Microscopy tools for nanoscale imaging and measurement are provided.
|
|
| domain | founded_year | HQ Location |
Nanofluidic scattering microscopy technology for biomolecule imaging is provided.
|
Frequently Asked Questions about SYNCELL
SYNCELL was founded in 2020 and raised its 1st funding round 4 years after it was founded.
SYNCELL is headquartered in Taipei, Taiwan.
Jung Chi Liao is the current CEO of SYNCELL. They have also founded this company.
SYNCELL is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series A of $15M, raised on Dec 11, 2024.
SYNCELL was founded in 2020 in Taipei, Taiwan, within the biotechnology sector. A microscopic platform called Microscoop is developed for identifying and quantifying proteins and biomarkers. Proprietary optoproteomics technology is employed, along with automated AI-based recognition algorithms and photochemical labeling reagents. These tools support discovery research and investigations into disease mechanisms, focusing on novel protein analysis.
SYNCELL's top competitors include Nearfield Instruments, Delmic B.V. and Fluid Imaging Technologies.
SYNCELL offers Microscoop and Reagent Kits.
SYNCELL has 1 investor. Key investors include Taiwania Capital.